Community Practice Considerations: Emerging Bispecific Antibodies in NHL

Podcast 1: Introduction to NHL: Epidemiology, Prognostication, and Treatment Strategies for Relapsed/Refractory NHL
Post-Test/Evaluation

Exit Survey
Questions marked with a * are required
24%
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Which of the following is not an FDA approved therapy option for patients with relapsed/refractory DLBCL:
Which of the following therapies is a bispecific antibody that is currently in clinical trials for the treatment of NHL:
A 55-year-old woman presents with GCB (not DEL) subtype of DLBCL. Her PET-CT shows FDG-avid adenopathy above and below diaphragm and she receives treatment with six cycles of R-CHOP and achieves a CR. She relapses a year later and is treated as part of a clinical trial with second-line axicabtagene ciloleucel, complicated by grade 3 CRS and grade 3 confusion. She is also treated with tocilizumab and dexamethasone, to address related toxicities and her PET-CT 30 days later shows a CR. Unfortunately, she relapses 3 months later with multistation adenopathy and a biopsy confirms a return of DLBCL, with CD19 and CD20 expression. Which of the following options is the most appropriate choice to treat this patient? 
Powered by QuestionPro